March 3, 2026Open Access

Reduced Frequency of Prolonged Sporadic Hemiplegic Migraine Attacks Following Fremanezumab Treatment—A Case Report

Key Points

Reduced frequency of prolonged hemiplegic migraine attacks was observed after treatment.
The notable improvement aligns with anecdotal evidence linking CGRP monoclonal antibodies to migraine relief.
The case emphasizes the diagnostic complexity associated with sporadic hemiplegic migraine attacks.
Findings indicate a need for further studies to establish treatment efficacy in this migraine subtype.

Abstract

This case illustrates the diagnostic complexity of SHM and adds to the growing body of anecdotal observations suggesting that CGRP monoclonal antibodies may be a promising preventive treatment for patients with HM. Further studies are needed to evaluate their efficacy in this rare migraine subtype.

Reduced Frequency of Prolonged Sporadic Hemiplegic Migraine Attacks Following Fremanezumab Treatment—A Case Report

Key Points

Abstract

Cite This Study